A Bayesian Optimal Interval Design Considering Efficacy and Toxicity in Early Phase Basket Trials
Pharmaceutical Statistics · 2026-07 · 25 (4)
DOI: 10.1002/pst.70108 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Statistics, online erschienen am 07.07.2026. Verfasst von Tomoyuki Kakizume und 3 weiteren Autor:innen. Beteiligte Einrichtung: Japan Biostatistics & Data Management Department, Daiichi Sankyo Co. Ltd, Tokyo, Japan. Hauptthemen laut MEDLINE: Antineoplastic Agents, Research Design, Neoplasms, Clinical Trials, Phase I as Topic. Die Arbeit nennt 35 Literaturangaben.
Abstract (Originalsprache)
Oncology drug development has increasingly shifted toward determining optimal biological doses rather than maximum tolerated doses (MTDs), particularly for targeted therapies and immunotherapies that exhibit complex dose‐efficacy relationships. Concurrently, basket trials have emerged as an efficient approach for evaluating investigational treatments across multiple cancer types sharing common molecular targets. We propose the BOIN‐ETB design, a model‐assisted dose‐finding design that addresses optimal dose (OD) identification in phase I/II basket trials by incorporating both toxicity and efficacy endpoints. The proposed approach employs common toxicity boundaries across cancer types while implementing cancer‐specific efficacy boundaries to account for differential efficacy responses between baskets. OD selection utilizes utility functions that quantify efficacy‐toxicity trade‐offs. Through comprehensive simulation studies across Fourteen realistic scenarios, the BOIN‐ETB design demonstrates robust performance in identifying true ODs while maintaining acceptable safety profiles across diverse cancer populations. The design provides superior consistency compared to alternative approaches, particularly in scenarios with heterogeneous dose‐efficacy relationships between cancer types, making it well‐suited for contemporary oncology dose‐finding basket trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Japan Biostatistics & Data Management Department, Daiichi Sankyo Co. Ltd, Tokyo, Japan.
- Quantitative Sciences and Evidence Generation, Astellas Pharma Global Development, Inc, Northbrook, Illinois, USA.
- Department or Health Science, Tokyo Medical University, Tokyo, Japan.
- Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
ORCID-Profile: Tomoyuki Kakizume, Kentaro Takeda, Masataka Taguri
Zitieren
APA
Kakizume, T., Takeda, K., Taguri, M., & Morita, S. (2026). A Bayesian Optimal Interval Design Considering Efficacy and Toxicity in Early Phase Basket Trials. Pharmaceutical Statistics, 25(4). https://doi.org/10.1002/pst.70108
Vancouver
Kakizume T, Takeda K, Taguri M, Morita S. A Bayesian Optimal Interval Design Considering Efficacy and Toxicity in Early Phase Basket Trials. Pharmaceutical Statistics. 2026;25(4). doi:10.1002/pst.70108
BibTeX
@article{Kakizume2026,
author = {Kakizume, Tomoyuki and Takeda, Kentaro and Taguri, Masataka and Morita, Satoshi},
title = {A Bayesian Optimal Interval Design Considering Efficacy and Toxicity in Early Phase Basket Trials},
journal = {Pharmaceutical Statistics},
year = {2026},
volume = {25},
number = {4},
doi = {10.1002/pst.70108}
}
EUVIMED